U.S. FDA's banner
U.S. FDA's profile picture

U.S. FDA

@US_FDA591,064 subscribers

Our posts are FDA Approved! Privacy Policy - https://t.co/LbTJXYRXVP FDA Authentic Accounts - https://t.co/w2LNbzG7M0

Shorts

FDA has issued 7 warning letters linked to 20+ violative products with concerns about GLP-1 and other products sold to consumers marked for “research purposes” or “not for human consumption”. These products may pose serious health risks. Do not use or purchase unapproved GLP-1 products marketed for research purposes.

FDA has issued 7 warning letters linked to 20+ violative products with concerns about GLP-1 and other products sold to consumers marked for “research purposes” or “not for human consumption”. These products may pose serious health risks. Do not use or purchase unapproved GLP-1 products marketed for research purposes.

1,382,150 Aufrufe

FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list. After careful review, we did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances. Public comment period now open. Learn more:

FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list. After careful review, we did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances. Public comment period now open. Learn more:

104,588 Aufrufe

The U.S. FDA has issued a "safe to proceed" letter allowing the initiation of an expanded access treatment protocol (EAP) for daraxonrasib, an experimental drug targeting pancreatic cancer. Per EAP guidelines, requests must be submitted to the sponsor by U.S.-licensed physicians on behalf of eligible patients. #FDA #PancreaticCancer

The U.S. FDA has issued a "safe to proceed" letter allowing the initiation of an expanded access treatment protocol (EAP) for daraxonrasib, an experimental drug targeting pancreatic cancer. Per EAP guidelines, requests must be submitted to the sponsor by U.S.-licensed physicians on behalf of eligible patients. #FDA #PancreaticCancer

50,617 Aufrufe

Today FDA approved the first-ever gene therapy for the treatment of genetic hearing loss under the National Priority Voucher Program. ✅6th approval under the National Priority Voucher Program ✅Approved 61 days after filing

Today FDA approved the first-ever gene therapy for the treatment of genetic hearing loss under the National Priority Voucher Program. ✅6th approval under the National Priority Voucher Program ✅Approved 61 days after filing

40,925 Aufrufe

Today, FDA approved a medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.

Today, FDA approved a medication for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.

71,841 Aufrufe

This Veterans Day, we thank all military veterans, including the many FDA employees who have served our nation.

This Veterans Day, we thank all military veterans, including the many FDA employees who have served our nation.

13,617 Aufrufe

#DrMartinLutherKingJr once said, "Of all the forms of inequality, injustice in health is the most shocking and inhumane.” The FDA remains committed to promote and protect the health of diverse populations through research and communication of science that address health disparities. Thank you, Dr. King, for your dream and commitment to equality for all.

#DrMartinLutherKingJr once said, "Of all the forms of inequality, injustice in health is the most shocking and inhumane.” The FDA remains committed to promote and protect the health of diverse populations through research and communication of science that address health disparities. Thank you, Dr. King, for your dream and commitment to equality for all.

20,417 Aufrufe

Videos

US_FDA's profile picture

Another busy week at FDA!

U.S. FDA

39,077 Aufrufe • vor 2 Monaten